News Opinion Editor's Corner TCT 2016 My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway Shelley Wood November 07, 2016
News Conference News TCT 2016 Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making Yael L. Maxwell November 02, 2016
News Conference News TCT 2016 Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients Todd Neale November 02, 2016
News Conference News TCT 2016 Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence Todd Neale November 01, 2016
Presentation TCT 2016 FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben November 01, 2016
Presentation TCT 2016 Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients! Presenter: Andreas Baumbach, David Hildick-Smith, Wilson Y. Szeto November 01, 2016
News Conference News TCT 2016 TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function Todd Neale November 01, 2016
Presentation TCT 2016 Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred! Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker October 31, 2016
Presentation TCT 2016 Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach! Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo October 31, 2016
Presentation TCT 2016 TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature Presenter: Niall T. Mulvihill, Michael Mahmoudi October 31, 2016
Presentation TCT 2016 Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position Presenter: Niall T. Mulvihill, Hellmuth Weich October 31, 2016
Presentation TCT 2016 Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position Presenter: Niall T. Mulvihill, Antoniette Neylon October 31, 2016
Presentation TCT 2016 Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis Presenter: Niall T. Mulvihill October 31, 2016
News Conference News TCT 2016 Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions Michael O'Riordan October 31, 2016
News Conference News TCT 2016 EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease Michael O'Riordan October 31, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR! Presenter: Russell A. Brandwein, Isaac George October 30, 2016
Presentation TCT 2016 Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It! Presenter: Russell A. Brandwein, Susheel K. Kodali October 30, 2016
Presentation TCT 2016 Real-world Requirements and Expectations for TAVR in Lower Risk Patients Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon October 30, 2016
Presentation TCT 2016 An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto October 30, 2016